Sold as Dermatop, Dermatop E Emollient. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 14, 2026, FDA lists 4 applications for Prednicarbate (sold as Dermatop, Dermatop E Emollient), first approved Sep 23, 1991, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Prednicarbate | Part D | $0K | -100% | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Clinical, Dermoscopic, and Mycological Evaluations of Resistant DermatophytosisFungal Skin Infection, Tinea Corporis · Sohag University | — | Not yet recruiting | Sep 1, 2026 |
| Sep 23, 1991 | DermatopNDA 19568 · New active ingredient | Valeant Pharms North | 5 | Discontinued |
| Oct 29, 1993 | Dermatop E EmollientNDA 20279 · New dosage form | Valeant Bermuda | 4 | Discontinued |
| Sep 19, 2006 | PrednicarbateANDA 77287 | Fougera Pharms | 1 | Discontinued |
| Mar 9, 2007 | PrednicarbateANDA 77236 | Fougera Pharms | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
